Clinical trials: Diseases of the Musculoskeletal System and Connective Tissue
- Condition Diseases of the Musculoskeletal System and Connective Tissue
- Funder type Industry (pharma, biotech, devices)
Rheumatoid Arthritis
A Study With CIT-013 in RA Patients
The goal of this clinical trial is to learn if CIT-013 works to treat rheumatoid arthritis in adults. It will also learn about the safety of CIT-013.
- Trial name
- Citydream (NCT06567470)
- Testing
- CIT-013 low dose, CIT-013 high dose, CIT-013 medium dose
- Where
- 20 sites in Belgium, Germany and 3 more
- Volunteers
- 96 people
- Sponsor
- Citryll BV
Systemic Lupus Erythematosus, Rheumatoid Arthritis
A Study to Learn About a Medicine Called PF-08154225 in Participants With Autoimmune Diseases
The purpose of this study is to learn about the safety and effects of the study medication called PF-08154225 for the potential treatment of autoimmune diseases.
- Conditions
- Systemic Lupus Erythematosus, Rheumatoid Arthritis, Idiopathic Inflammatory Myositis, Systemic Sclerosis
- Trial name
- NCT07782450
- Testing
- PF-08154225
- Volunteers
- 54 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
A Study to Evaluate the Safety of Escalating Doses of Ocrelizumab in Subjects With Rheumatoid Arthritis
This is a randomized, placebo-controlled, multicenter, blinded Phase I/II, investigator and subject-blinded study of the safety of escalating doses of ocrelizumab in combination with MTX in subjects with moderate to severe RA
- Trial name
- NCT00077870
- Testing
- ocrelizumab
- Volunteers
- 237 people
- Sponsor
- Genentech, Inc.
Moderate to Severe Psoriatic Arthritis
Extension Study of Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis (CDDY391A12201-extension)
The purpose of this 1-year open-label extension study is to characterize the longer-term safety and tolerability of DDY391 and to assess the durability of clinical response in participants with Psoriatic Arthritis (PsA) who have…
- Trial name
- NCT07923773
- Testing
- DDY391
- Volunteers
- 88 people
- Sponsor
- Novartis Pharmaceuticals
Rheumatoid Arthritis
An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis
This prospective, multi-center, observational study will assess the efficacy and safety of treatment in patients who are treated with a TNF Inhibitor or RoActemra/Actemra (tocilizumab) as the first biologic therapy.
- Trial name
- NCT01543503
- Where
- 154 sites in Argentina, Belgium and 14 more
- Volunteers
- 1,225 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis (RA)
Evaluation of Patient Performance Using the Metoject Device for Subcutaneous Injection in Rheumatoid Arthritis (RA)Patient
To evaluate the human factors/usability of Rheumatoid Arthritis (RA) patients with the Metoject® prefilled pen (including a label comprehension assessment and a device robustness evaluation).
- Trial name
- NCT01871961
- Testing
- Methotrexate (Metoject® prefilled pen)
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- medac GmbH
Rheumatoid Arthritis
A Study to Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy
This study will evaluate the efficacy and safety of ocrelizumab, compared to placebo, in patients with active rheumatoid arthritis who have an inadequate response to methotrexate therapy.
- Trial name
- FEATURE (NCT00673920)
- Testing
- Methotrexate, Ocrelizumab
- Volunteers
- 314 people
- Sponsor
- Genentech, Inc.
Arthritis, Rheumatoid
A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate Therapy
The purpose of this study is to evaluate the efficacy of ustekinumab and CNTO 1959 in reducing the signs and symptoms of disease in patients with active rheumatoid arthritis (RA) despite concomitant methotrexate (MTX) therapy and…
- Trial name
- NCT01645280
- Testing
- Ustekinumab + MTX (Group 2), Ustekinumab + MTX (Group 3), CNTO 1959 + MTX (Group 4)
- Where
- 47 sites in United States, Argentina and 9 more
- Volunteers
- 274 people
- Sponsor
- Janssen Research & Development, LLC
Rheumatoid Arthritis
A Multiple Dose of HL237 in Healthy Male Subject
HL237 is a new autoimmune therapeutic agent for rheumatoid arthritis, including the basic structure of biguanide in metformin, an existing diabetes drug. The immune modulating activity of HL237 was demonstrated in animal model.
- Trial name
- NCT03896594
- Testing
- HL237
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Hanlim Pharm. Co., Ltd.
Inflammatory Bowel Disease
Analysis of Birth Outcomes of Swedish, Danish and Finnish Women Exposed to Remicade With Inflammatory Bowel Disease, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Psoriasis
The purpose of this study is collection and analysis of information pertaining to pregnancy outcomes in women exposed to infliximab during pregnancy, relative to the background risk in similar but non-biologic exposed patients…
- Trial name
- NCT00658827
- Testing
- No intervention
- Volunteers
- 370 people, healthy volunteers welcome
- Sponsor
- Janssen Biotech, Inc.
Arthritis, Psoriatic, Psoriasis
Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Rheumatologists
The purpose of this study is to evaluate the safety and effectiveness of etanercept under usual care settings in patients with PsA treated by rheumatologists.
- Conditions
- Arthritis, Psoriatic, Psoriasis, Skin Diseases, Papulosquamous
- Trial name
- NCT00293722
- Testing
- Etanercept
- Where
- Germany
- Volunteers
- 1,308 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy
Study Design \& Objectives: Multi-centre, non-interventional, open-label, non-comparative, prospective cohort study with a clinical follow-up between 12 and 14 weeks.
- Trial name
- PRINT (NCT01299545)
- Where
- 37 sites in Canada, France and 6 more
- Volunteers
- 123 people
- Sponsor
- TcLand Expression S.A.
Rheumatoid Arthritis
Study to Characterize the Pharmacokinetics of a Single Dose of SC Abatacept 125 mg Using the BD Autoinjector or the Prefilled Syringe
The primary purpose of the protocol is to describe the pharmacokinetics of a single dose of Abatacept 125 mg in Rheumatoid Arthritis patients delivered via the autoinjector device or the approved prefilled syringe.
- Trial name
- NCT01890473
- Testing
- Abatacept
- Where
- 25 sites in United States, Argentina and 3 more
- Volunteers
- 356 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
Study Comparing Two VAY736 Drug Products in Patients With Rheumatoid Arthritis
This study will assess the safety and pharmacokinetic comparability of two VAY736 drug products in patients with rheumatoid arthritis.
- Trial name
- NCT03574545
- Testing
- ianalumab
- Where
- 2 sites in Germany, Jordan
- Volunteers
- 48 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis, Psoriatic Arthritis
Study to Assess the Safety and Change in Disease Symptoms of Risankizumab (Skyrizi) in Adult Participants With Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis
Plaque Psoriasis is a chronic inflammatory disease in which skin cells build up and develop scaly red and white patches on the skin.
- Trial name
- NCT04433442
- Where
- 63 sites in South Korea
- Volunteers
- 2,324 people
- Sponsor
- AbbVie
Sjogren Syndrome
Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome
A randomized, double-blind, placebo controlled, 2-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjogren's syndrome (NEPTUNUS-1)
- Trial name
- NEPTUNUS-1 (NCT05350072)
- Testing
- VAY736
- Where
- 77 sites in United States, Austria and 16 more
- Volunteers
- 275 people
- Sponsor
- Novartis Pharmaceuticals
Rheumatoid Arthritis
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a TNF-Blocker.
This single arm study will evaluate the efficacy and safety of MabThera in patients with active rheumatoid arthritis whose current treatment with one or more TNF blocker had produced an inadequate response.
- Trial name
- NCT00424502
- Testing
- rituximab [MabThera/Rituxan], Methotrexate
- Where
- 3 sites in Hungary
- Volunteers
- 20 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Evaluate the Safety, Tolerability, Pharmacokinetics,and Clinical Activity of FB704A
The cause of Rheumatoid Arthritis (RA) is not fully understood. However, one of the substances secreted by certain cells in the body, interleukin-6 (IL-6), is believed to play a major role in chronic inflammation that is typical…
- Trial name
- NCT03890302
- Testing
- FB704A
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Fountain Biopharma Inc.
Rheumatoid Arthritis
A Study To Evaluate The Effect Of Food On How Tasocitinib (CP-690,550) Is Absorbed And Moves Through The Body Following Oral Administration Of Tasocitinib (CP-690,550) Tablets To Healthy Subjects
In this study, a 10 mg tasocitinib (CP-690,550) tablet will be administered to healthy subjects on two separate dosing occasions.
- Trial name
- NCT01184001
- Testing
- Treatment A, Treatment B
- Where
- Singapore
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer
Psoriasis, Arthritis
Safety and Efficacy of BFH772 in Psoriasis Patients
This study will determine the efficacy of topical BFH772 in psoriasis patients and the safety after multiple dosing.
- Trial name
- NCT00987870
- Testing
- BFH772, calcipotriol/betamethasone
- Where
- Germany
- Volunteers
- 15 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.